Detalhe da pesquisa
1.
Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age.
N Engl J Med
; 389(24): 2245-2255, 2023 Dec 14.
Artigo
Inglês
| MEDLINE | ID: mdl-38091531
2.
Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting.
Ann Intern Med
; 177(2): 189-195, 2024 02.
Artigo
Inglês
| MEDLINE | ID: mdl-38190712
3.
Clinical Epidemiology and Risk Factors for Critical Outcomes Among Vaccinated and Unvaccinated Adults Hospitalized With COVID-19-VISION Network, 10 States, June 2021-March 2023.
Clin Infect Dis
; 78(2): 338-348, 2024 02 17.
Artigo
Inglês
| MEDLINE | ID: mdl-37633258
4.
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings.
N Engl J Med
; 385(15): 1355-1371, 2021 10 07.
Artigo
Inglês
| MEDLINE | ID: mdl-34496194
5.
Vaccine Effectiveness Against Influenza-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2021-2022 Season, VISION Network.
J Infect Dis
; 228(2): 185-195, 2023 07 14.
Artigo
Inglês
| MEDLINE | ID: mdl-36683410
6.
Protection of Two and Three mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized With COVID-19-VISION Network, August 2021 to March 2022.
J Infect Dis
; 227(8): 961-969, 2023 04 18.
Artigo
Inglês
| MEDLINE | ID: mdl-36415904
7.
Protection From COVID-19 mRNA Vaccination and Prior SARS-CoV-2 Infection Against COVID-19-Associated Encounters in Adults During Delta and Omicron Predominance.
J Infect Dis
; 227(12): 1348-1363, 2023 06 15.
Artigo
Inglês
| MEDLINE | ID: mdl-36806690
8.
Influenza vaccine effectiveness against influenza-A-associated emergency department, urgent care, and hospitalization encounters among U.S. adults, 2022-2023.
J Infect Dis
; 2023 Dec 02.
Artigo
Inglês
| MEDLINE | ID: mdl-38041853
9.
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022.
MMWR Morb Mortal Wkly Rep
; 71(53): 1637-1646, 2023 Mar 17.
Artigo
Inglês
| MEDLINE | ID: mdl-36921274
10.
Safety Monitoring of JYNNEOS Vaccine During the 2022 Mpox Outbreak - United States, May 22-October 21, 2022.
MMWR Morb Mortal Wkly Rep
; 71(49): 1555-1559, 2022 Dec 09.
Artigo
Inglês
| MEDLINE | ID: mdl-36480476
11.
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022.
MMWR Morb Mortal Wkly Rep
; 71(5152): 1616-1624, 2022 Dec 30.
Artigo
Inglês
| MEDLINE | ID: mdl-36580430
12.
Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022.
MMWR Morb Mortal Wkly Rep
; 71(42): 1335-1342, 2022 Oct 21.
Artigo
Inglês
| MEDLINE | ID: mdl-36264840
13.
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
MMWR Morb Mortal Wkly Rep
; 71(4): 139-145, 2022 Jan 21.
Artigo
Inglês
| MEDLINE | ID: mdl-35085224
14.
Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.
MMWR Morb Mortal Wkly Rep
; 71(13): 495-502, 2022 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35358170
15.
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
MMWR Morb Mortal Wkly Rep
; 71(7): 255-263, 2022 Feb 18.
Artigo
Inglês
| MEDLINE | ID: mdl-35176007
16.
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022.
MMWR Morb Mortal Wkly Rep
; 71(9): 352-358, 2022 Mar 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35239634
17.
Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022.
MMWR Morb Mortal Wkly Rep
; 71(29): 931-939, 2022 Jul 22.
Artigo
Inglês
| MEDLINE | ID: mdl-35862287
18.
COVID-19 Vaccination Coverage Among Insured Persons Aged ≥16 Years, by Race/Ethnicity and Other Selected Characteristics - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 15, 2021.
MMWR Morb Mortal Wkly Rep
; 70(28): 985-990, 2021 Jul 16.
Artigo
Inglês
| MEDLINE | ID: mdl-34264911
19.
Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021.
MMWR Morb Mortal Wkly Rep
; 70(44): 1539-1544, 2021 Nov 05.
Artigo
Inglês
| MEDLINE | ID: mdl-34735425
20.
Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.
MMWR Morb Mortal Wkly Rep
; 70(44): 1553-1559, 2021 Nov 05.
Artigo
Inglês
| MEDLINE | ID: mdl-34735426